All In Biotech

Drug Trial Radar · NCT07417917

QLS12010 Capsules in Adults With Moderate to Severe Hidradenitis Suppurativa

A Multicenter Phase II Clinical Trial Evaluating the Efficacy and Safety of QLS12010 Capsules in Adult Participants With Moderate-to-Severe Hidradenitis Suppurativa

Last checked: Nov 19, 2026Latest source record: Feb 18, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Not yet recruitingPivotal-lookingRandomized with 102 participants. This is a heuristic, not a regulatory label.

Status

Not yet recruiting

Enrollment

102

Planned (sponsor's estimate)

Start

Apr 1, 2026

Primary completion

Jun 1, 2027

Study completion May 2028

Sponsor

Lead sponsor
Qilu Pharmaceutical Co., Ltd.Industry
Sponsor type
Industry
First posted
Feb 18, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a Phase II clinical study to evaluate the safety, efficacy, pharmacokinetics and pharmacodynamics of QLS12010 capsules in the treatment of moderate to severe Hidradenitis Suppurativa (HS). The study is comprised of two parts: Part A is a multi-center, open-label, single-dose group proof-of-concept study; Part B is a randomized, double-blind, placebo-controlled dose-ranging study. The overall duration of this study is up to 32 weeks, inclusive of the Screening Period, Treatment Period of up to 24 weeks, and the 4-Week Follow-Up Period for safety assessment.

Conditions

  • Adults With Moderate-to-severe Hidradenitis Suppurativa

Interventions

  • QLS12010Drug

    QLS12010 oral capsules

  • PlaceboDrug

    Matching placebo oral capsules

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percent Change form Baseline in a total abscess and inflammatory nodule(AN) count [Part B]Time frame: Week 16
  2. Incidence and severity of treatment emergent Adverse Events [Part A]Time frame: up to approximately 24 weeks

Locations

No sites are listed on the registry yet.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.